Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suvaro is a brand of rosuvastatin calcium, a synthetic lipid-lowering agent in the statin class, specifically available in an orally disintegrating tablet (ODT) formulation in South Korea. It is used to treat dyslipidemia, hypercholesterolemia, and hypertriglyceridemia. As a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, it blocks the conversion of HMG-CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. This inhibition primarily occurs in the liver, leading to increased expression of LDL receptors on the surface of hepatocytes, which enhances the uptake and catabolism of LDL from the blood. The ODT version, developed by BCWorld Pharm and marketed by Hanlim Pharm, is designed to dissolve rapidly on the tongue without water, providing a convenient alternative for patients with dysphagia or those seeking improved adherence through more flexible administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Suvaro.